# US 2023/0407259 A1 · De-differentiated fibroblast-conditioned media for stimulation of disc regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0407259 A1
- Document ID: US20230407259A1
- Status: Published application
- Kind: A1
- Application number: 18/345,022
- Filed: 2023-06-30
- Published: 2023-12-21
- Earliest claimed: 2018-05-04
- Assignees: SpinalCyte, LLC
- Applicants: Spinalcyte, LLC
- Inventors: Pete O'HEERON; Thomas ICHIM
- Web page: https://patentgrep.com/patent/US20230407259A1

## CPC

- C12N 5/0656: {Adult fibroblasts}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 35/33: Fibroblasts
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2502/02: embryonic cells
- C12N 2502/1323: Adult fibroblasts
- C12N 2502/45: Artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the disclosure include methods and compositions for disc repair in a mammal using conditioned media (and/or one or more components therefrom) from fibroblasts that have been de-differentiated and cultured optionally with one or more particular conditions and/or compositions. In specific cases, fibroblasts that have been de-differentiated are exposed to hypoxia, histone deacetylase inhibitor(s), DNA methyltransferase inhibitor(s), or a combination thereof, and the conditioned media therefrom is provided in an effective amount to an individual.

## Claims

### Claim 1

A method of treating or preventing disc degeneration in an individual, comprising the step of providing to the individual an effective amount of conditioned media from culture of de-differentiated fibroblasts or one or more components therefrom.

### Claim 2 (depends on 1)

The method of claim 1, wherein the conditioned media comprises exosomes.

### Claim 3 (depends on 2)

The method of claim 2, wherein the exosomes express markers selected from the group consisting of a) CD63; b) CD9; c) MHC I; d) CD56; and e) a combination thereof.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, further comprising the step of de-differentiating the fibroblasts to produce de-differentiated fibroblasts.

### Claim 5 (depends on 4)

The method of claim 4, wherein the step of de-differentiating the fibroblasts to produce de-differentiated fibroblasts occurs in culture.

### Claim 6 (depends on 4, 5)

The method of claim 4 or 5, wherein the de-differentiated fibroblasts are produced upon exposure to stem cells and/or cytoplasm from stem cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the stem cells are pluripotent stem cells selected from the group consisting of a) parthenogenic stem cells; b) embryonic stem cells; c) inducible pluripotent stem cells; d) somatic cell nuclear transfer derived stem cells; e) Stimulus-triggered acquisition of pluripotency (STAP); and f) a combination thereof.

### Claim 8 (depends on 4, 5, 6, 7)

The method of any one of claims 4-7, wherein the de-differentiated fibroblasts are produced upon exposure to hypoxia.

### Claim 9 (depends on 4, 5, 6, 7, 8)

The method of any one of claims 4-8, wherein the de-differentiated fibroblasts are produced upon exposure to one or more histone deacetylase inhibitors.

### Claim 10 (depends on 9)

The method of claim 9, wherein the histone deacetylase inhibitor is selected from the group consisting of a) valproic acid; b) trichostatin A; c) phenylbutyrate; d) vorinostat; e) belinostat; f) LAQ824; g) panobinostat; h) entinostat; i) CI994; j) mocetinostat; k) sulforaphane; and l) a combination thereof.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 4-10, wherein the de-differentiated fibroblasts are produced upon exposure to one or more DNA methyltransferase inhibitors.

### Claim 12 (depends on 11)

The method of claim 11, wherein the DNA methyltransferase inhibitor is selected from the group consisting of a) decitabine; b) 5-azacytidine; c) Zebularine; d) RG-108; e) procaine hydrochloride; f) Procainamide hydrochloride; g) Hydralazine hydrochloride; h) Epigallocatechin gallate; i) Chlorogenic acid; j) Caffeic acid; and h) a combination thereof.

### Claim 13 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 4-12, wherein the de-differentiated fibroblasts are produced upon exposure to 2%-8%, 2%-7%, 2%-6%, 2%-5%, 2%-4%, 2%-3%, 3%-8%, 3%-7%, 3%-6%, 3%-5%, 3%-4%, 4%-8%, 4%-7%, 4%-6%, 4%-5%, 5%-8%, 5%-7%, 5%-6%, 6%-8%, 6%-7%, or 7%-8% oxygen.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein exosomes are obtained from de-differentiated fibroblasts.

### Claim 15 (depends on 14)

The method of claim 14, wherein the exosomes are purified from culture of the de-differentiated fibroblasts using anion exchange chromatography, high performance liquid chromatography (HPLC), or both.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, comprising administering to the individual one or more of hyperbaric oxygen, adipose stem cell administration, bone marrow mesenchymal stem cell administration, fibroblast administration, and a combination thereof.

### Claim 17

A composition comprising conditioned media from culture of de-differentiated fibroblasts or one or more components therefrom.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the conditioned media comprises exosomes.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the exosomes express markers selected from the group consisting of a) CD63; b) CD9; c) MHC I; d) CD56; and e) a combination thereof.
